Literature DB >> 19058256

The human promyelocytic leukemia protein is a tumor suppressor for murine skin carcinogenesis.

Victoria M Virador1, Rafael E Flores-Obando, Adam Berry, Rinal Patel, Julia Zakhari, Yu-Chien Lo, Kathryn Strain, Joanna Anders, Christophe Cataisson, Laura A Hansen, Stuart H Yuspa.   

Abstract

Expression of the PMLRARalpha fusion dominant-negative oncogene in the epidermis of transgenic mice resulted in spontaneous skin tumors attributed to changes in both the PML and RAR pathways [Hansen et al., Cancer Res 2003; 63:5257-5265]. To determine the contribution of PML to skin tumor susceptibility, transgenic mice were generated on an FVB/N background, that overexpressed the human PML protein in epidermis and hair follicles under the control of the bovine keratin 5 promoter. PML was highly expressed in the epidermis and hair follicles of these mice and was also increased in cultured keratinocytes where it was confined to nuclear bodies. While an overt skin phenotype was not detected in young transgenic mice, expression of keratin 10 (K10) was increased in epidermis and hair follicles and cultured keratinocytes. As mice aged, they exhibited extensive alopecia that was accentuated on the C57BL/6J background. Following skin tumor induction with 7, 12-dimethylbenz[a]anthracene (DMBA) as initiator and 12-O-tetradecanoylphorbol-13-acetate (TPA) as promoter, papilloma multiplicity and size were decreased in the transgenic mice by 35%, and the conversion of papillomas to carcinomas was delayed. Cultured transgenic keratinocytes underwent premature senescence and upregulated transcripts for p16 and Rb but not p19 and p53. Together, these changes suggest that PML participates in regulating the growth and differentiation of keratinocytes that likely influence its activity as a suppressor for tumor development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19058256      PMCID: PMC2711034          DOI: 10.1002/mc.20498

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  40 in total

Review 1.  PML protein isoforms and the RBCC/TRIM motif.

Authors:  K Jensen; C Shiels; P S Freemont
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

2.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins.

Authors:  Carmela Gurrieri; Paola Capodieci; Rosa Bernardi; Pier Paolo Scaglioni; Khedoudja Nafa; Laura J Rush; David A Verbel; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

3.  The expression of keratin k10 in the basal layer of the epidermis inhibits cell proliferation and prevents skin tumorigenesis.

Authors:  Mirentxu Santos; Jesus M Paramio; Ana Bravo; Angel Ramirez; José L Jorcano
Journal:  J Biol Chem       Date:  2002-03-11       Impact factor: 5.157

4.  Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway.

Authors:  Lei Li; Dalin He; Hui He; Xinyang Wang; Linlin Zhang; Yong Luo; Xunyi Nan
Journal:  Cancer Lett       Date:  2005-10-10       Impact factor: 8.679

5.  p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB.

Authors:  Shuling Zhang; Xiaolan Qian; Chanelle Redman; Valeri Bliskovski; Edward S Ramsay; Douglas R Lowy; Beverly A Mock
Journal:  Oncogene       Date:  2003-04-17       Impact factor: 9.867

Review 6.  Role of PML and the PML-nuclear body in the control of programmed cell death.

Authors:  Rosa Bernardi; Pier Paolo Pandolfi
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

7.  A PMLRARA transgene results in a retinoid-deficient phenotype associated with enhanced susceptibility to skin tumorigenesis.

Authors:  Laura A Hansen; Diane Brown; Victoria Virador; Takemi Tanaka; Fausto Andreola; Kathryn Strain; Barbara Dancheck; Rebeccah Riley; Jeffrey M Arbeit; Luigi M De Luca; Scott Kogan; Stuart H Yuspa
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

8.  PML is a direct p53 target that modulates p53 effector functions.

Authors:  Elisa de Stanchina; Emmanuelle Querido; Masako Narita; Ramana V Davuluri; Pier Paolo Pandolfi; Gerardo Ferbeyre; Scott W Lowe
Journal:  Mol Cell       Date:  2004-02-27       Impact factor: 17.970

9.  Overexpression of the promyelocytic leukemia gene suppresses growth of human bladder cancer cells by inducing G1 cell cycle arrest and apoptosis.

Authors:  Dalin He; Xunyi Nan; Kun-Song Chang; Yafeng Wang; Leland W K Chung
Journal:  Chin Med J (Engl)       Date:  2003-09       Impact factor: 2.628

10.  Role of promyelocytic leukemia (PML) protein in tumor suppression.

Authors:  E M Rego; Z G Wang; D Peruzzi; L Z He; C Cordon-Cardo; P P Pandolfi
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  4 in total

1.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

Review 2.  Targeting survival pathways in chronic myeloid leukaemia stem cells.

Authors:  A Sinclair; A L Latif; T L Holyoake
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

3.  Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications.

Authors:  Erika L Abel; Joe M Angel; Kaoru Kiguchi; John DiGiovanni
Journal:  Nat Protoc       Date:  2009-08-27       Impact factor: 13.491

4.  Pten loss in Lgr5+ hair follicle stem cells promotes SCC development.

Authors:  Haiyan Chen; Xusheng Wang; Yu Chen; Jimin Han; Deqiang Kong; Meizhong Zhu; Xiaobing Fu; Yaojiong Wu
Journal:  Theranostics       Date:  2019-10-22       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.